ZEVRA THERAPEUTICS, INC.
ZVRA · XNASCIK 1434647fmd_0DNP2N4QECV88Z0WYZVHT0JHV4Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2013 to Sep 30, 2026, 52 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | 0 | 13 | 13 | 29 | 10 | 27 | 24 | 106 |
| Cost of revenue | – | – | 0 | 10 | – | 2 | 0 | 3 | – | – |
| Gross profit | – | – | 0 | 3 | – | 27 | 10 | 25 | – | – |
| Research and development | 20 | 21 | 42 | 19 | 9 | 10 | 20 | 40 | 42 | 13 |
| Selling, general and administrative | – | – | – | – | – | – | 15 | 34 | 55 | 78 |
| Total operating expenses | 37 | 33 | 56 | – | – | – | – | – | – | – |
| Operating income | (37) | (33) | (56) | (20) | (6) | 8 | (43) | (50) | (87) | (63) |
| Interest expense | 6 | 6 | 5 | 5 | 5 | 0 | 0 | 2 | 7 | 8 |
| Interest and investment income | 0 | 0 | 0 | 0 | – | – | – | – | – | – |
| Other non-operating income (expense) | 21 | (10) | (1) | (4) | (7) | (16) | 16 | 4 | (3) | 150 |
| Income before taxes | (17) | (43) | (57) | (25) | (13) | (9) | (27) | (46) | (90) | 87 |
| Income tax expense | (0) | (0) | (0) | (0) | (0) | 0 | (0) | 0 | 15 | 3 |
| Net income from continuing operations | (17) | (43) | (56) | (25) | (13) | (9) | (27) | (46) | (106) | 83 |
| Net income | (17) | (43) | (56) | (25) | (13) | (9) | (27) | (46) | (106) | 83 |
| Net income to common shareholders | – | – | – | – | (13) | (63) | (27) | (46) | (106) | 78 |